Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SIM0417 + ritonavir + midazolam
- Development stage
- Unknown
- Lead developer
- Simcere Pharmaceutical Group
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
SIM0417 (also known as simnotrelvir or SSD8432) is an orally administered small-molecule inhibitor targeting the coronavirus main protease (3CLpro), developed for the treatment of COVID-19. Ritonavir is co-administered as a pharmacokinetic enhancer to inhibit CYP3A-mediated metabolism and increase systemic exposure of SIM0417. Midazolam is a short-acting benzodiazepine and a sensitive substrate of CYP3A4, often used in drug-drug interaction studies to assess CYP3A inhibition. The combination "SIM0417 + ritonavir + midazolam" has been studied in healthy volunteers to evaluate pharmacokinetic interactions; co-administration with ritonavir significantly increases plasma concentrations of midazolam due to strong inhibition of CYP3A4 by ritonavir and weak inhibition by simnotrelvir[1][2][5]. This combination is not intended for therapeutic use but rather for clinical pharmacology research on drug-drug interactions.
- Brand names
- Simnotrelvir/ritonavir
- Other names
- simnotrelvir/ritonavir + midazolamSSD8432/ritonavir + midazolam
02
Targets
CYP3A4 (Cytochrome P450 3A4)GABRR (GABA-A receptor subunit rho)Mpro (3C-like proteinase of SARS-CoV-2)PR (Progesterone receptor)
Beyond the preview
Go deeper on SIM0417 + ritonavir + midazolam.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SIM0417 + ritonavir + midazolam.